Added to YB: 2025-07-17
Pitch date: 2025-07-16
IDXG [bullish]
Interpace Biosciences, Inc.
+18.47%
current return
Author Info
Elias’ Investing Journal shares value investing and special situation stock ideas. Sign up for the newsletter.
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
Market Cap
$3.9M
Pitch Price
$0.98
Price Target
2.88 (+106%)
Dividend
N/A
EV/EBITDA
0.70
P/E
2.61
EV/Sales
0.14
Sector
Health Care Providers and Services
Category
turnaround
A Microcap Diagnostic Company Trading at 2x Earnings and Growing at 19% - Interpace Biosciences, Inc.
IDXG: Molecular diagnostics co focused on thyroid cancer risk tests (90% rev). After PancraGEN discontinuation drove 77% stock crash, co is restructuring around growing thyroid biz (+19% YoY). Trades at 2.4x EV/EBITDA, 4.4x FCF. PE-backed turnaround story targeting 2026 uplisting & sale. Risks: Medicare reimbursement changes, FDA regulation.
Read full article (8 min)